Proposed experiment from debate on Microglia activate astrocytes via IL-1alpha/TNF/C1q, and reactive astrocytes fee

SUMMARY

# Proposed experiment from debate on Microglia activate astrocytes via IL-1alpha/TNF/C1q, and reactive astrocytes fee ## Background and Rationale This study addresses the critical limitation of DREADD (Designer Receptors Exclusively Activated by Designer Drugs) technology in chronic neurodegeneration models by testing long-term expression stability and functional efficacy over extended periods. While DREADDs provide powerful tools for selective cell-type manipulation, their utility in chronic di

METHODOLOGY NOTES

**Phase 1: DREADD Construct Preparation and Validation (Weeks 1-2)** • Design and synthesize hM3Dq, hM4Di, and rM3Ds DREADD constructs with fluorescent reporters • Validate construct integrity via sequencing and western blot analysis • Transfect HEK293T cells (n=24 per construct) for initial functional validation • Perform dose-response curves with CNO (0.1-100 μM) and measure cAMP/IP3 levels **Phase 2: Neuronal Cell Line Transduction and Long-term Expression (Weeks 3-26)** • Transduce SH-SY5Y neuroblastoma cells (n=144 per DREADD type) with lentiviral vectors • Monitor DREADD expression via flow cytometry and immunofluorescence at weeks 1, 4, 8, 16, and 24 • Assess cell viability using MTT assays and lactate dehydrogenase release • Measure DREADD functional response using calcium imaging and electrophysiology monthly **Phase 3: Chronic Disease Model Implementation (Weeks 4-26)** • Establish amyloid-beta (5 μM) and tau (P301S) aggregation models in transduced cells • Apply oxidative